Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study
Authors:
- 1 December 2024
- journal article
- research article
- Published by SAGE Publications in Viral Immunology
- Vol. 37 (10) , 480-488
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, in December 2019, has led to global efforts in vaccination to mitigate rising morbidity and mortality, with vaccines proving crucial in controlling the pandemic. This study evaluated the humoral responses to the inactivated virus vaccine Sinopharm or Koxing Kerlafor, the protein subunit vaccine ZF001, and the adenoviral vector vaccine Convidecia after 18 months of inactivated virus vaccination by heterologous and homologous booster vaccination in patients with previous SARS-CoV-2 infection and healthy individuals. We discovered that patients who had recovered from the infection and then received a third vaccine dose (booster) exhibited durable immunity. Furthermore, the heterologous booster vaccine induced higher neutralizing antibody responses compared with the homologous booster. These findings offer valuable insights into the efficacy of different COVID-19 vaccine strategies following booster immunization.Keywords
This publication has 33 references indexed in Scilit:
- Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccineHeliyon, 2023
- Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life studyRevista Española de Geriatría y Gerontología, 2023
- Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort studyeClinicalMedicine, 2022
- Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemicThe Lancet, 2022
- Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort studyThe Lancet Global Health, 2022
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studyThe Lancet, 2022
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsThe Lancet Infectious Diseases, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional studyThe Lancet, 2021
- Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)Journal of General Internal Medicine, 2020